Thyroid Uptake Study in a Patient on Amiodarone
A 71-year-old man with atrial fibrillation on amiodarone for 14 months presents with palpitations, heat intolerance, and a 6 kg weight loss over 3 months. TSH is suppressed, free T4 is elevated, and total T3 is mildly elevated. He has a history of hypertension and chronic kidney disease stage 3 (eGFR 42). The endocrinologist requests a radioactive iodine uptake and scan to distinguish amiodarone-induced thyrotoxicosis type 1 (iodine-induced, excess hormone synthesis) from type 2 (destructive thyroiditis). The patient is currently on amiodarone 200 mg daily and has been for over a year. He also takes a multivitamin containing iodine.
1. What are the limitations of the radioiodine uptake study in this patient, and how should the result be interpreted?
Read the worked answer
Amiodarone is roughly 37% iodine by weight and produces a large iodine load that suppresses thyroidal radioiodine uptake for months after discontinuation, and the patient is still taking it. A low or unmeasurable 24-hour uptake is therefore expected and does not by itself distinguish type 1 from type 2 disease. In type 1, uptake may be low-normal or low because of the iodine load despite excess synthesis; in type 2, uptake is also low because the gland is not synthesizing. The uptake study is thus of limited discriminatory value here. Interpretation should combine uptake with thyroid volume, vascularity on Doppler, thyroid antibody status, and the clinical course. A trial of glucocorticoids (type 2 responds) versus thionamide plus beta-blockade (type 1) is often used when the distinction is unclear. The multivitamin iodine further confounds the study.
2. If the uptake is 2% at 24 hours and the gland is normal-sized with low vascularity, what is your working diagnosis and management approach, and what safety considerations apply?
Read the worked answer
A low 24-hour uptake (2%) with a normal-sized, low-vascularity gland favors type 2 amiodarone-induced thyrotoxicosis (destructive thyroiditis). Management is supportive: beta-blockade for symptoms, and glucocorticoids (e.g., prednisone) to reduce thyroidal inflammation; thionamides are generally ineffective because there is no excess synthesis. Because the patient has CKD stage 3, contrast and nephrotoxic agents should be avoided, and any glucocorticoid course requires monitoring of glucose and blood pressure. Amiodarone should not be stopped abruptly without cardiology input, since it is controlling his atrial fibrillation and withdrawal can precipitate arrhythmia; however, the thyroid team should coordinate with cardiology about whether continuation is appropriate. Radioiodine therapy is not useful in type 2 disease with low uptake and would be ineffective while the iodine load persists. Follow-up TSH and free T4 should guide tapering.